Supporting Information available: Experimental
details for the synthesis and characterization of select
compounds and procedures for the biochemical and
cellular assays are included in the supporting
information. This material is available free of charge
Smith, A.; Wan, Y.; Wang, X.; Xie, Y.; Zhang, Q.;
Appleton, B.; Dollinger, G.; Isbell, J.; Li, C.; Li, N.;
Sethuraman, V.; Stuart, D.; Sun, F.; Turner, N.; Xu, Y.;
Zang, R.; Poon, D.; Tellew, J., Discovery of LGX818, a
potent, selective RAF kinase inhibitor for treatment of
BRAFV600E-positive melanoma. 245th ACS National
Meeting, April 7-11 (2013), MEDI-277.
References and Notes
6. De Buck, S.; Heieber, W.; Vitaliti, A.; Straube, F.;
Emotte, C.; Bruin, G.; Woessner, R., Population PK-PD
Model for Tolerance Evaluation to the p38 MAP Kinase
Inhbitor BCT197. Pharmacometrics Syst. Pharmacol.
2015, 4, 691-700.
1. Davies, H.; Bignell, G. R.; Cox, C.; Stephens, P.;
Edkins, S.; Clegg, S.; Teague, J.; Woffendin, H.; Garnett,
M. J.; Bottomley, W.; Davis, N.; Dicks, E.; Ewing, R.;
Floyd, Y.; Gray, K.; Hall, S.; Hawes, R.; Hughes, J.;
Kosmidou, V.; Menzies, A.; Mould, C.; Parker, A.;
Stevens, C.; Watt, S.; Hooper, S.; Wilson, R.; Jayatilake,
H.; Gusterson, B. A.; Cooper, C.; Shipley, J.; Hargrave,
D.; Pritchard-Jones, K.; Maitland, N.; Chenevix-Trench,
G.; Riggins, G. J.; Bigner, D. D.; Palmieri, G.; Cossu, A.;
Flanagan, A.; Nicholson, A.; Ho, J. W. C.; Leung, S. Y.;
Yuen, S. T.; Weber, B. L.; Seigler, H. F.; Darrow, T. L.;
Paterson, H.; Marais, R.; Marshall, C. J.; Wooster, R.;
Stratton, M. R.; Futreal, P. A., Mutations of the BRAF
gene in human cancer. Nature 2002, 417, 949-954.
2. Asati, V.; Bharti, S.K.; Mahapatra, D.K., Mutant B-
RAF Kinase Inhibitors as Anticancer Agents. Anti-
Cancer Agents Med Chem 2016, 16, 1558-1575.
7. Hayman, S.R.; Leung, N.; Grande, J.P.; Garovic,
V.D., VEGF Inhibition, Hypertension, and Renal
Toxicity. Curr. Oncol. Rep. 2012, 14, 285-294.
8. Mobitz, H., The ABC of Protein Kinase
conformations. Biochim. Biophys. Acta 2015, 1555-1566.
9. Roskoski Jr., R., Classification of small molecule
protein kinase inhibitors based upon the structures of
their drug-enzyme complexes. Pharmacol. Res. 2016,
103, 26-48.
10. Zhao, Z.; Wu, H.; Wang, L.; Liu, Y.; Knaff, S.; Liu,
Q.; Gray, N.S., Exploration of Type II Binding Mode: A
Privileded Approach for Kinase Inhibitor Focused Drug
Discovery? ACS Chem. Biol. 2014, 9, 1230-1241.
11. Unpublished results.
3. Williams, T.E.; Subramanian, S.; Verhagen, J.;
McBride, C.M.; Costales, A.; Sung, L.; Antonio-McCrea,
W.; McKenna, M.; Louie, A.K.; Ramurthy, S.; Levine,
B.; Shafer, C.M.; Machajewski, T.; Renhowe, P.A.;
Appleton, B.A.; Amiri, P.; Chou, J.; Stuart, D.; Aardalen,
K.; Poon, D., Discovery of RAF265: A Potent mut-B-
RAF inhibitor for the treatment of metastatic melanoma.
ACS Med. Chem. Lett. 2015, 6(9), 961-965.
12. Pargellis, C.; Tong, L.; Churchill, L.; Cirillo, P.;
Gilmore, T.; Graham, A.; Grob, P.; Hickey, E.; Moss, N.;
Pav, S.; Regan, J., Inhibition of p38 MAP kinase by
utilizing a novel allosteric binding site. Nature Struct.
Biol. 2002, 9, 268 - 272.
13. Hamdouchi, C.; Sanchez, C.; Ezquerra, J.,
Chemoselective
aminoimidazo[1,2-a]pyridines
bis(trifluoroacetate) (PIFA). Synthesis 1998, 6, 867-872.
arylsulfenylation
of
2-
pipeline/encorafenib-lgx818/.
by phenyliodine(III)
5.
Chen, Z.; Costales, A.; Dillon, M.; Huang, S.;
Huang, Z.; Jin, J.; Liu, Z.; Machajewski, T.; Madera, A.;
Antonios-McCrea, W.; McKenna, M.; Pan, S.; Pecchi,
S.; Renhowe, P.; Sendzik, M.; Shafer, C.; Sharma, A.;